Migraine Drugs Linked to Higher Miscarriage Risk
A new observational study suggests anti-CGRP monoclonal antibodies may be associated with increased pregnancy loss.
Updated on Oct. 12, 2026 in Pregnancy
Research published in JAMA Neurology found that exposure to anti-CGRP monoclonal antibodies was linked to a 40 percent higher risk of miscarriage. The study analyzed insurance data from 7,579 pregnancies in the United States, focusing on outcomes during the first 20 weeks of gestation.
Why it matters
Understanding this potential link is critical for patients managing migraines, as researchers believe these medications might interfere with vital processes like embryo implantation and placental development. Because this was an observational study, it provides important context for those planning pregnancy to consider alongside their doctor.
This observational study of 7,579 pregnancies analyzed outcomes using U.S. insurance data collected between 2018 and 2021. Researchers compared miscarriage rates within the first 20 weeks of pregnancy for those exposed to anti-CGRP medications versus those who were not.
The players
JAMA Neurology
A peer-reviewed medical journal that publishes research on the nervous system and neurological disorders.
The details
Anti-CGRP monoclonal antibodies are designed to block the calcitonin gene-related peptide pathway. The study authors suggest that because CGRPs naturally play a role in regulating blood flow and supporting embryo implantation and placental development, blocking them may inadvertently disrupt these early stages of pregnancy. In contrast, the study found no such association with propranolol exposure.
Timeline
2018-2021: Data collection period for the insurance patient records.
October 2026: Research findings were published in JAMA Neurology.
Health Landscape
This research updates the current clinical management of migraine in reproductive-age populations, where safety data for newer biologics has been limited. It highlights the need for continued investigation into how modern migraine treatments intersect with early pregnancy biology.
If you are currently pregnant or planning a pregnancy, it is worth discussing your migraine management plan and any prescribed medications with your physician. They can help you evaluate the risks and benefits of your current treatment based on the latest safety data.
The takeaway
The study suggests a potential association between anti-CGRP monoclonal antibodies and pregnancy loss that requires further verification. Patients should prioritize a conversation with their neurologist or OB-GYN to review their current migraine regimen and discuss safer alternatives if necessary.
Further reading
For more information on navigating medication use during pregnancy, visit our Pregnancy section.
Source note: This article includes information reported by ScienceAlert.
